Subscribe to Newsletter
Business & Regulation Business Practice, Marketing, Standards & Regulation, Small Molecules

Teva Takes Hit in New York Opioid Case

Credit: Leonhard Niederwimmer /

A jury has found Teva Pharmaceuticals USA and its affiliates guilty of contributing to New York’s opioid crisis. Another trial will now be held to decide how much the company will pay. New York Attorney General Letitia James filed a suit against Teva and other pharmaceutical companies in 2019 for allegedly engaging in deceptive marketing practices about the dangers of opioids.

In a statement from 2019, James said, “The opioid epidemic has ravaged families and communities across New York. We found that pharmaceutical manufacturers and distributors engaged in years of deceptive marketing about the risks of opioids and failed to exercise their basic duty to report suspicious behavior, leading to the crisis we are living with today. As the Sackler Family and the other defendants grew richer, New Yorkers’ health grew poorer and our state was left to foot the bill. The manufacturers and distributors of opioids are to blame for this crisis and it is past time they take responsibility.”

The other companies named in the original lawsuit all reached settlements with the state ahead of the trial: in June 2021, J&J agreed to pay $230 million; McKesson, Cardinal Health and Amerisource Bergen agreed to a $1.1 billion settlement in July; Endo paid $50 million in September; and in December 2021 – in the closing days of the trial – Abbvie’s Allergan agreed to pay $200 million, leaving Teva as the sole defender.

Teva “strongly disagrees” with the outcome and will be preparing an appeal. In a statement, the company said, “In NY, the plaintiffs presented no evidence of medically unnecessary prescriptions, suspicious or diverted orders, no evidence of oversupply by the defendants – or any indication of what volumes were appropriate – and no causal relationship between Teva’s conduct including its marketing and any harm to the public in the state.”

This lawsuit is specific to New York, but thousands of opioid cases are being seen all over the US. And a streamlined National Prescription Opiate Litigation has consolidated numerous lawsuits against J&J and the three largest distributors in the US: McKesson, Cardinal Health, and Amerisource Bergen; settlements have already been reached in this national litigation, with J&J paying up to $5 billion and the distributors up to $22.8 billion.

But opioid manufacturers and distributors are not always in the losing camp. In California in November 2021, a judge tentatively cleared the named companies (J&J, Teva, Abbvie, and Endo) of any wrongdoing.

Opioid prescriptions began drastically increasing in the 1990s. According to the CDC, from 1999 to 2019, nearly 247,000 people in the US died from overdoses involving prescription opioids.

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

Related White Papers
Nitrosamines Risk Mitigation: The critical role of excipients and supplier qualification

| Contributed by DFE Pharma GmbH & Co. KG

Performance validation of ScatterX78 against NIST reference materials

| Contributed by Malvern Panalytical

Early stage product development using laser diffraction analysis

| Contributed by Malvern Panalytical

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine